[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565856":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":49,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"VR Headset","EXPERIMENTAL",null,[13],"Device: VR headset",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","VR headset","The VR portion of the study will last for 8 weeks. You will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like.",[9],[21],{"name":22,"affiliation":5,"role":23},"Jami Kinnucan, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Lauren P Loeb, MD","CONTACT","904-953-6970","loeb.lauren@mayo.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Mayo Clinic Florida","RECRUITING","Jacksonville","Florida","32224","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-81.65565,30.33218,{"lat":43,"lon":42},[46,48],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":47},"researchparticipantadvocate@mayo.edu",{"name":22,"role":23,"phone":11,"phoneExt":11,"email":11},{"type":23,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Jami A. Kinnucan","Principal Investigator","100565856","a-pilot-study-to-assess-the-safety-tolerability-and-efficacy-of-virtual-reality-for-the-treatment-of-abdominal-pain-in-quiescent-crohns-disease-100565856",false,"NCT06647615","A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease","Inclusion Criteria:\n\n* Patients with a diagnosis of endoscopically and histologically confirmed CD with evidence of C-reactive protein \\< 5 mg\u002FdL and fecal calprotectin \\< 150microg\u002Fg who also report any abdominal pain at least weekly will be included.\n\nExclusion Criteria:\n\n* Patients will be excluded from the study if they do not have biopsy-proven CD, have a known seizure disorder, if symptoms are thought to represent an organic disorder, those with visual or hearing impairments, if symptoms represent a known pelvic floor disorder, if the patient is using opioids, has significant ongoing psychological distress (HAD score \\> 11 for either anxiety or depression), or if the patient can not actively participate in the study for any other reason (e.g., inability to understand English as the VR program as an English only).","ALL","18 Years","70 Years",{"count":62,"type":63},15,"ESTIMATED","INTERVENTIONAL",[66],"NA","The purpose of this research is to see if patients with Crohn's disease (CD) and abdominal pain resulting in health-related quality of life deficits despite lack of evidence of active inflammation improve with the use of virtual reality (VR).",[69,70],"Crohn's Disease","Abdominal Pain (AP)",[69,72],"Quiescent Crohn's Disease","2026-02-12",{"date":75,"type":76},"2026-02-17","ACTUAL",{"date":78,"type":76},"2024-05-24",{"date":80,"type":63},"2026-12-31",{"name":5,"class":6},1]